Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Qtempo

Product Description
Cardiac ion channels function in a sequential and interactive manner to drive the beating of cardiomyocytes. QTempo is the only human pre-clinical functional assay that can capture the complexity of that process. The underlying idea is simple: We (1) generate clusters of spontaneously beating cardiomyocytes from human iPS cells, (2) place these beating cardiomyocytes in a well with electrodes to monitor electropotential, and (3) Measure the effect of compounds and drugs on the waveform.

From this simple idea, the QTempo assay allows analysis of the full range of ion channels. QTempo directly measures not only QT interval, but also a range of other cardiac action potential parameters (such as beat rate and the QRS complex). QTempo identifies compounds that affect Na, K and Ca ion channels and reflects their complex interactions.

Uses beating human heart cells:
* Identifies beat rate dependent effects
* Identifies compounds that change beat rate
* Covers all cardiomyocyte ion channels
* Screens non-ion channel factors
* Faster, cheaper and kinder than using animals
The cardiomyocyte clusters used in QTempo generate robust, consistent data over extended periods. This allows a wide variety of drug concentrations to be sequentially tested, increasing confidence in drug safety before further development.

ReproCELL’s QTempo assay is offered in a variety of formats to suit customer requirements. ReproCELL is licensed by iPS Academia (Kyoto, Japan) to use iPS technology in this assay.

In all our tests, including assays of cardiotoxic compounds not correctly identified by the hERG assay, QTempo has generated results in complete agreement with clinical findings.

Two key technologies developed by ReproCELL underlie QTempo. The first is a protocol for the differentiation of cardiomyocytes from both ES and iPS cells. Secondly, ReproCELL has developed novel protein-free media that maintain the cardiomyocytes whilst allowing stable measurement of electropotential.
Product Qtempo
Company ReproCell Products
Price Request a quote
More Information View company product page
Catalog Number RCESD005
Quantity Unspecified
Company Logo

ReproCell Products
Reprocell Inc KDX Shin-yokohama 381 Bldg 8F 3-8-11, Shin-yokohama, Kohoku-ku, Yokohama Kanagawa 222-0033, Japan

Tel: +81 45-475-3887
Fax: +81 45-474-1006
Email: info_repro@reprocell.com



Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!